Advances in Hepatology (Record no. 45415)

MARC details
000 -LEADER
fixed length control field 02253naaaa2200373uu 4500
001 - CONTROL NUMBER
control field https://directory.doabooks.org/handle/20.500.12854/77570
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220219213820.0
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number intechopen.91512
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781839686245
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781839686238
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781839686252
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.5772/intechopen.91512
Terms of availability doi
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title English
042 ## - AUTHENTICATION CODE
Authentication code dc
072 #7 - SUBJECT CATEGORY CODE
Subject category code MJJ
Source bicssc
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Rodrigo, Luis
Relationship edt
245 10 - TITLE STATEMENT
Title Advances in Hepatology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. IntechOpen
Date of publication, distribution, etc. 2021
300 ## - PHYSICAL DESCRIPTION
Extent 1 electronic resource (258 p.)
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open Access
Source of term star
Standardized terminology for access restriction Unrestricted online access
520 ## - SUMMARY, ETC.
Summary, etc. This book discusses clinical advances in hepatology, with a focus on metabolic diseases and chronic hepatitis C. The development of direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection in 2010 has completely transformed the management of this disease. This transformative nature of DAA therapy underpins the goal of the World Health Organization (WHO) to eliminate HCV infection as a public health threat by 2030. The advantages of using these therapies include high efficacy (sustained virological response rate >95%) with minimal side effects, good tolerability, easy drug administration (once-daily oral dosing) and short duration of treatment (8-12 weeks). The commercialization of second-generation DAA agents due to their high effectiveness, few side-effects and pangenotypic action. This transformative nature of DAA therapy underpins the goal of the WHO to eliminate HCV infection as a public health threat by 2030.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons
Use and reproduction rights https://creativecommons.org/licenses/by/3.0/
Source of term cc
-- https://creativecommons.org/licenses/by/3.0/
546 ## - LANGUAGE NOTE
Language note English
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hepatology
Source of heading or term bicssc
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Martins, Ian
Relationship edt
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Guo, Xiaozhong
Relationship edt
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Qi, Xingshun
Relationship edt
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Rodrigo, Luis
Relationship oth
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Martins, Ian
Relationship oth
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Guo, Xiaozhong
Relationship oth
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Qi, Xingshun
Relationship oth
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://www.intechopen.com/books/10326">https://www.intechopen.com/books/10326</a>
Access status 0
Public note DOAB: download the publication
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://directory.doabooks.org/handle/20.500.12854/77570">https://directory.doabooks.org/handle/20.500.12854/77570</a>
Access status 0
Public note DOAB: description of the publication

No items available.